Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 16UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Non-squamous Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Esophageal Squamous Cell Carcinoma 1Desmoid Tumors 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Tamoxifen 10Docetaxel 8Trastuzumab 7Paclitaxel 6Letrozole 6Gemcitabine 6Exercise 6Control Groups 6exemestane 5Indocyanine Green 5Cyclophosphamide 5Carboplatin 5Anastrozole 5pertuzumab 4dalpiciclib 4Vinorelbine 4Doxorubicin 4Capecitabine 4pyrotinib 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Fulvestrant 3Cisplatin 3ferumoxides 2Zoledronic Acid 2Tablets 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Breast Neoplasms × anlotinib × Clear all
NCT05296577 2023-09-25

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
134 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡